Physician profile
Joseph Daniel Mannen
NPI 1851827034
$3,015.92
in general payments reported to CMS, 2019-2025
20 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $143 · 2021: $490 · 2022: $489 · 2023: $384 · 2024: $415 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $743.88 | 2019-2024 | Rocklatan, Rhopressa |
| Bausch & Lomb Americas INC. | $563.82 | 2022-2025 | Miebo, Infuse, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $460.13 | 2020-2021 | |
| Sight Sciences, INC. | $275.64 | 2021-2023 | Tearcare System |
| Glaukos Corporation | $146.41 | 2024-2025 | Idosetr, Idose, Ce-Marked Kxla System |
| Amgen INC. | $144.55 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $103.20 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $92.31 | 2021-2023 | Cequa |
| Coopervision INC. | $71.40 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $69.91 | 2021-2024 | Tecnis Simplicity, Lipiflow System Activator (Disposable) |
| Oyster Point Pharma, INC. | $68.32 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Rxsight INC | $61.22 | 2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Harrow Eye, LLC | $50.87 | 2024 | Vevye |
| Abbvie INC. | $40.46 | 2023 | |
| Lensar, INC. | $33.01 | 2025 | Lensar Laser System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $25.35 | 2024 | Oxervate |
| Biotissue Holdings INC. | $23.78 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $18.32 | 2022 | |
| Thea Pharma INC. | $17.77 | 2024 | Iyuzeh |
| Optos, INC. | $5.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mannen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.